Ayca Gucalp

List of Publications by Year
in descending order

28 papers	3,333 citations	361413 20 h-index	526287 27 g-index
28 all docs	28 docs citations	28 times ranked	5316 citing authors

#	Article	IF	Citations
1	Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations. Modern Pathology, 2022, 35, 396-402.	5.5	9
2	A phase 2 clinical trialâ€¯assessing theâ€¯efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic tripleâ€negative breast cancer. Cancer, 2020, 126, 850-860.	4.1	116
3	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 6149-6157.	7.0	29
4	Mammographic screening in male patients at high risk for breast cancer: is it worth it?. Breast Cancer Research and Treatment, 2019, 177, 705-711.	2.5	18
5	â€œA Tool, Not a Crutchâ€: Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering. Journal of Oncology Practice, 2019, 15, e277-e288.	2.5	28
6	Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Research and Treatment, 2019, 173, 37-48.	2.5	205
7	A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. Cancer Prevention Research, 2018, 11, 203-214.	1.5	17
8	The microbial flora of taxane therapyâ€“associated nail disease in cancer patients. Journal of the American Academy of Dermatology, 2018, 78, 607-609.	1.2	5
9	Enzalutamide for the Treatment of Androgen Receptorâ€“Expressing Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2018, 36, 884-890.	1.6	365
10	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. Breast Cancer Research and Treatment, 2018, 171, 111-120.	2.5	38
11	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. Cancer Prevention Research, 2017, 10, 235-243.	1.5	114
12	A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer. Clinical Cancer Research, 2017, 23, 4046-4054.	7.0	43
13	Androgen receptorâ€positive, tripleâ€negative breast cancer. Cancer, 2017, 123, 1686-1688.	4.1	14
14	Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1692-1701.	3.6	77
15	The Androgen Receptor: Is It a Promising Target?. Annals of Surgical Oncology, 2017, 24, 2876-2880.	1.5	22
16	Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. Journal of Clinical Oncology, 2016, 34, 4270-4276.	1.6	578
17	Targeting the androgen receptor in triple-negative breast cancer. Current Problems in Cancer, 2016, 40, 141-150.	2.0	70
18	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. Clinical Cancer Research, 2016, 22, 2283-2289.	7.0	154

#	Article	IF	Citations
19	Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression. Seminars in Oncology, 2016, 43, 154-160.	2.2	27
20	Menopause Is a Determinant of Breast Adipose Inflammation. Cancer Prevention Research, 2015, 8, 349-358.	1.5	90
21	American Society of Clinical Oncology Position Statement on Obesity and Cancer. Journal of Clinical Oncology, 2014, 32, 3568-3574.	1.6	418
22	A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease.. Journal of Clinical Oncology, 2014, 32, TPS1615-TPS1615.	1.6	2
23	Phase II Trial of Bicalutamide in Patients with Androgen Receptorâ€“Positive, Estrogen Receptorâ€“Negative Metastatic Breast Cancer. Clinical Cancer Research, 2013, 19, 5505-5512.	7.0	592
24	The Androgen Receptor in Breast Cancer: Biology and Treatment Considerations. Current Breast Cancer Reports, 2012, 4, 56-65.	1.0	0
25	Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer. Clinical Breast Cancer, 2011, 11, 306-311.	2.4	118
26	Triple-Negative Breast Cancer: Adjuvant Therapeutic Options. Chemotherapy Research and Practice, 2011, 2011, 1-13.	1.6	50
27	Spectrum of HIV lymphoma 2009. Current Opinion in Hematology, 2010, 17, 362-367.	2.5	17
28	Triple-Negative Breast Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 62-65.	2.0	117